Lymphoma (non-Hodgkin's) Cancer Other and unspecified types of non-Hodgkin's lymphoma
Conditions
Interventions
1. CHOP regimen: Chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisolone repeated every 21 days for 6-8 cycles
2. PmitCEBO regimen: Chemotherapy with mitoxantrone
Sponsors
British National Lymphoma Investigation (BNLI) (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Previously untreated non-Hodgkin's Lymphoma of the following types: follicular large cell lymphoma, diffuse mixed cell lymphoma diffuse large cell lymphoma diffuse immunoblastic lymphoma 0r Revised European/American Lymphoma (REAL) classification: diffuse large B peripheral T cell lymphoma 2. Bulky stage IA and stages IB-IV (Ann Arbour staging system) 3. Age 18-59 years 4. Measurable or evaluable disease 5. Good prognosis, defined as the presence of no more than one of the following adverse features: Stage III/IV Lactic dehydrogenase (LDH) >upper limit of normal Performance status 2-4 (Eastern Cooperative Oncology Group [ECOG]-World Health Organisation [WHO]) Adequate bone marrow function, indicated by Haemoglobin =10 g/dL Neutrophils =2 x 10^9/L Platelets =100 x 10^9/L 6. Written informed consent
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed